Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cue Biopharma Inc V.CUE


Primary Symbol: CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.


NDAQ:CUE - Post by User

Bullboard Posts
Post by I_luv_GVGon Oct 16, 2007 10:12pm
204 Views
Post# 13584599

Cue closes $2.5-million second tranche

Cue closes $2.5-million second trancheHello everyone, Cue closes $2.5-million second tranche 2007-10-16 20:06 ET - News Release Mr. Rahoul Sharan reports On Oct. 16, 2007, Cue Capital Corp. closed the second tranche of the private placement financing subscribed for by Cameco Global Exploration Ltd. as reported in Stockwatch on Sept. 5, 2007. The second tranche funding consisted of the placement of 1,572,327 units at a price of $1.59 per unit for private placement proceeds of $2.5-million. Each unit consisted of one share of Cue and one-half share purchase warrant with one full warrant being exercisable at a price of $2.14 to purchase one additional share of Cue for a period of two years from the date of closing. The shares and warrants and any shares of Cue acquired on the exercise of the warrants were or will be issued subject to a four-month hold expiring on Feb. 17, 2008. By virtue of the private placement, Cameco Global Explorations Ltd., a wholly owned subsidiary of Cameco Corporation, the world's largest uranium producer, now holds 4,219,385 common shares of Cue representing 15.4 per cent of the issued and outstanding shares of Cue as at Oct. 16, 2007, and 2,109,692 warrants, which if exercised would give rise to the issuance of 2,109,692 shares. A concurrent release with respect to the transaction is being made by Cameco. The proceeds of the second tranche of the private placement will be primarily used by Cue for uranium exploration and development programs within the approximately 236,000 hectare Yuty uranium project located in the districts of Felgencio Yegros, Yuty and Leandro Oviedo, in the departments of Cazaapa and Itapua, Paraguay. GLTA, I_luv_GVG
Bullboard Posts